Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) Price Target at $13.75

Theravance Biopharma, Inc. (NASDAQ:TBPH) has been assigned an average rating of “Hold” from the five research firms that are currently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $13.75.

TBPH has been the subject of a number of analyst reports. Leerink Partnrs lowered Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 6th. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Theravance Biopharma in a research report on Monday, September 16th. Leerink Partners lowered shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $15.00 to $10.00 in a research report on Tuesday, August 6th. StockNews.com downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, August 10th. Finally, TD Cowen dropped their price objective on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating for the company in a report on Tuesday, August 6th.

Insider Buying and Selling at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 4,000 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the transaction, the senior vice president now directly owns 322,743 shares in the company, valued at approximately $2,904,687. This represents a 1.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Theravance Biopharma

Several large investors have recently added to or reduced their stakes in the stock. Barclays PLC boosted its holdings in shares of Theravance Biopharma by 279.9% in the third quarter. Barclays PLC now owns 65,580 shares of the biopharmaceutical company’s stock valued at $529,000 after purchasing an additional 48,316 shares during the period. Y Intercept Hong Kong Ltd bought a new position in shares of Theravance Biopharma during the 3rd quarter worth $251,000. XTX Topco Ltd increased its stake in shares of Theravance Biopharma by 34.5% during the third quarter. XTX Topco Ltd now owns 20,439 shares of the biopharmaceutical company’s stock valued at $165,000 after buying an additional 5,243 shares during the period. Jane Street Group LLC raised its holdings in shares of Theravance Biopharma by 1.1% in the third quarter. Jane Street Group LLC now owns 144,575 shares of the biopharmaceutical company’s stock valued at $1,165,000 after acquiring an additional 1,640 shares in the last quarter. Finally, PDT Partners LLC lifted its stake in Theravance Biopharma by 31.2% in the third quarter. PDT Partners LLC now owns 87,177 shares of the biopharmaceutical company’s stock worth $703,000 after acquiring an additional 20,738 shares during the period. 99.10% of the stock is owned by hedge funds and other institutional investors.

Theravance Biopharma Price Performance

NASDAQ:TBPH opened at $9.52 on Thursday. The firm has a market capitalization of $465.72 million, a price-to-earnings ratio of -9.43 and a beta of 0.25. The business has a fifty day moving average price of $8.42 and a 200-day moving average price of $8.70. Theravance Biopharma has a one year low of $7.44 and a one year high of $11.71.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.23%. The company had revenue of $16.87 million for the quarter, compared to the consensus estimate of $16.11 million. During the same quarter last year, the firm posted ($0.17) earnings per share. On average, equities research analysts expect that Theravance Biopharma will post -1.04 earnings per share for the current fiscal year.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.